Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 739 matching trials from the live ClinicalTrials.gov search.
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older · Male only
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Chicago, Illinois + 5 more
Conditions
Brain Injury, Central Nervous System Degenerative Disorder, Central Nervous System Infectious Disorder, Central Nervous System Vascular Malformation, Hemorrhagic Cerebrovascular Accident, Ischemic Cerebrovascular Accident, Primary Brain Neoplasm, Brain Cancer, Brain Tumors
Interventions
Ferumoxytol, Tissue Analysis, Magnetic Resonance Imaging
Drug · Other · Procedure
Lead sponsor
Michael Iv
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Conditions
Childhood Kidney Neoplasm, Clear Cell Renal Cell Carcinoma, Congenital Mesoblastic Nephroma, Rhabdoid Tumor of the Kidney
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Human Immunodeficiency Virus
Interventions
flexible sigmoidoscopy or colonoscopy with biopsies
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
10 Years to 21 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
WATS-3D tissue sampling prior to forceps biopsies, WATS-3D tissue sampling following forceps biopsies
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Conditions
Breast Cancer
Interventions
protein analysis, protein expression analysis, proteomic profiling, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, liquid chromatography, mass spectrometry, fine-needle aspiration, needle biopsy, radiomammography
Genetic · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Duarte, California
Terminated No phase listed Observational

Intubated ICU Patients

NCT02171091
Conditions
Patients Requiring Endotracheal Intubation
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Melanoma (Skin)
Interventions
carboplatin, paclitaxel albumin-stabilized nanoparticle formulation
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
156
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 98 more
Conditions
Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
gene expression analysis, microarray analysis, polymorphism analysis, proteomic profiling, flow cytometry, immunologic technique, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Conditions
Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Nonmalignant Neoplasm, Precancerous Condition
Interventions
bronchoscopic and lung imaging studies, diagnostic bronchoscopy, histopathologic examination, optical coherence tomography
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Recruiting No phase listed Observational

Prostate Tissue BioBank

NCT06659614
Conditions
Prostate Cancer, Genetic Predisposition
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection, MK6240
Other · Radiation
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
22
States / cities
Atlantis, Florida • Aventura, Florida • Clermont, Florida + 19 more
Conditions
Leukemia, Lymphoma
Interventions
biologic sample preservation procedure
Other
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
1,873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
214
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 156 more
Conditions
Obesity
Interventions
Adults presenting for surgery in the neck area
Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
8 Years to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2034
U.S. locations
1
States / cities
Sacramento, California
Completed Early Phase 1 Interventional

NIH CCR2 AAA Study

NCT04586452
Conditions
Abdominal Aortic Aneurysm (AAA), No Abdominal Aortic Aneurysm (Non-AAA)
Interventions
AAA Group (Aim 3A), Non-AAA Group, Ex Vivo Human AAA Specimens (Aim 2A), Relationship between radiotracer and CCR2 (Aim 2B), AAA Group (Aim 3B-Reproducibility)
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Probiotic, Therapeutic Conventional Surgery
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Completed No phase listed Observational Accepts healthy volunteers

Exploration and Determination of Genomic Markers Predictive of Uterine Atony

NCT03413917
Conditions
Uterine Atony
Interventions
Analysis of genomic markers in uterine atony
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Biospecimen Collection, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, Carboplatin, Celecoxib, Cobimetinib, Copanlisib, Dabrafenib, Dacomitinib, Darolutamide, Dasatinib, Doxorubicin, Durvalumab, Enasidenib, Entrectinib, Enzalutamide, Erlotinib, Everolimus, Fluorouracil, Idelalisib, Imatinib, Ipilimumab, Lenvatinib, Leucovorin, Lorlatinib, Losartan, Nab-paclitaxel, Neratinib, Nivolumab, Olaparib, Oxaliplatin, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Ponatinib, Quality-of-Life Assessment, Regorafenib, Ruxolitinib, Sirolimus, Sorafenib, Sunitinib, Trametinib, Trastuzumab Emtansine, Tretinoin, Vemurafenib, Venetoclax, Vismodegib, Vorinostat
Drug · Biological · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Lateral Gluteal Depression
Interventions
Biopsies
Diagnostic Test
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Completed Not applicable Interventional Accepts healthy volunteers

Determining Normal Range for Free Light Chains in Serum Among Twins

NCT04191057
Conditions
Multiple Myeloma
Interventions
Free light chains
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Completed No phase listed Observational Accepts healthy volunteers

Immune Signature of Palmoplantar Pustulosis

NCT01780857
Conditions
Palmoplantar Pustulosis
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas